MedTrace Logo

Icotinib Following Chemotherapy Versus Chemotherapy as Adjuvant Therapy in Stage IIA-IIIA NSCLC With EGFR Mutation

NCT01996098 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 251

Last updated 2024-09-05

No results posted yet for this study

Summary

The purpose of this study is studying icotinib following chemotherapy to see how well it works compared to chemotherapy in treating patients with resected stage IIA-IIIA NSCLC harboring EGFR mutation.

Conditions

Interventions

DRUG

6-month Icotinib

125 mg three times daily (375 mg per day) by mouth for 6 months

DRUG

12-month icotinib

125 mg three times daily (375 mg per day) by mouth for 12 months

Sponsors & Collaborators

  • Sun Yat-sen University

    lead OTHER

Principal Investigators

  • Si-Yu Wang, MD · Sun Yat-sen University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-01-01
Primary Completion
2021-12-31
Completion
2024-02-15

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01996098 on ClinicalTrials.gov